Anti-PD-1/PD-L1 antibodies
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anti-PD-1/PD-L1 antibodies, covering 2025-08-19 to 2025-08-19. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade [Phase 2]